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Plasma rich in growth factors (PRGF) is a subtype of platelet-rich plasma (PRP) that
stimulates tissue regeneration andmay promote neuronal survival. It has been employed in
ophthalmology to achieve tissue repair in some retinal pathologies, although how PRGF
acts in the retina is still poorly understood. As a part of the central nervous system, the
retina has limited capacity for repair capacity following damage, and retinal insult can
provoke the death of retinal ganglion cells (RGCs), potentially producing irreversible
blindness. RGCs are in close contact with glial cells, such as Müller cells, that help
maintain homeostasis in the retina. In this study, the aim was to determine whether PRGF
can protect RGCs and whether it increases the number of Müller cells. Therefore, PRGF
were tested on primary cell cultures of porcine RGCs and Müller cells, as well as on co-
cultures of these two cell types. Moreover, the inflammatory component of PRGF was
analyzed and the cytokines in the different PRGFs were quantified. In addition, we set out
to determine if blocking the inflammatory components of PRGF alters its effect on the cells
in culture. The presence of PRGF compromises RGC survival in pure cultures and in co-
culture with Müller cells, but this effect was reversed by heat-inactivation of the PRGF. The
detrimental effect of PRGF on RGCs could be in part due to the presence of cytokines and
specifically, to the presence of pro-inflammatory cytokines that compromise their survival.
However, other factors are likely to be present in the PRGF that have a deleterious effect on
the RGCs since the exposure to antibodies against these cytokines were insufficient to
protect RGCs. Moreover, PRGF promotesMüller cell survival. In conclusion, PRGF hinders
the survival of RGCs in the presence or absence of Müller cells, yet it promotes Müller cell
survival that could be the reason of retina healing observed in the in vivo treatments, with
some cytokines possibly implicated. Although PRGF could stimulate tissue regeneration,
further studies should be performed to evaluate the effect of PRGF on neurons and the
implication of its potential inflammatory role in such processes.
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INTRODUCTION
As a part of the central nervous system (CNS), the retina has a
limited capacity for repair after disease or lesion. Different
diseases affect retinal ganglion cells (RGCs), the neurons
responsible for communication between the eye and the brain.
RGCs die by apoptosis in glaucoma, a neurodegenerative disease
that provokes irreversible blindness (Glovinsky et al., 1991;
Garcia-Valenzuela et al., 1995; Quigley et al., 1995; Quigley,
2011). However, they can also die following axon degeneration
(Knoferle et al., 2010), ischemia (Selles-Navarro et al., 1996; Joo
et al., 1999) or in diabetes (Lieth et al., 2000; Zhang et al., 2000).
Nevertheless, it has been seen that RGCs can recover their
regenerative capacities in appropriate environments (Garcia
et al., 2002; Berry et al., 2008; Ruzafa and Vecino, 2015;
Vecino et al., 2015).
Plasma rich in growth factors (PRGF), a subtype of P-PRP
(pure platelet-rich plasma), is a supernatant enriched in plasma
and platelet-derived morphogens, proteins and growth factors.
PRGF represents a complex pool of active mediators that may
stimulate and accelerate tissue regeneration, which is generally
safe to use and inexpensive to obtain. Indeed, autologous PRGF
has been approved for clinical use by the European Community
and the U.S. Food and Drug Administration (Anitua et al.,
2014b), and it is generally employed in ophthalmology as eye
drops to treat the ocular surface (Lopez-Plandolit et al., 2010;
Lopez-Plandolit et al., 2011). Furthermore, different PRPs are
being used in clinic: autologous platelet injections are being used
to treat recurrent retinal detachment (Nadal et al., 2012) and pilot
studies are being carried out to use PRGF in retinal surgery to
treat persistent macular holes (Arias et al., 2019). Although visual
acuity may be improved in patients, these treatments could be
associated with complications such as focal macular epithelial
pigmentary hypertrophy, retinal folds emanating from the
macula, development of epiretinal membrane or cataract
progression (Cheung et al., 2005; Nugent and Lee, 2015).
Thus, although PRGF has been successfully used, the events
that could be triggered by PRGF in the retina are not
completely understood.
An intranasal delivery system has been used with human
PRGF to reverse neurodegeneration and rescue memory in a
transgenic mouse model of Alzheimer’s disease (AD). Moreover,
PRGF can exert a neurotrophic effect in response to amyloid beta
and promote neuronal survival (Anitua et al., 2015a). Since PRGF
could offer neuroprotection and it is approved for use in clinical
practice, we set out to study if PRGF can protect RGCs and
enhance the survival of these cells.
RGCs are in close contact with Müller glia, the main glial cells
in the mammalian retina. These cells that serve to maintain
retinal homeostasis, and they are involved in retinal metabolism,
in the phagocytosis of neuronal debris, in the release of certain
transmitters and trophic factors, as well as in K+ uptake (reviewed
in (Vecino et al., 2016)). Müller cells extend across the thickness
of the retina, providing structural stability and maintaining close
contact with the majority of retinal neurons (Bringmann and
Reichenbach, 2001). In addition to their involvement in
maintaining homeostasis, these cells also provide trophic
factors to neurons that potentially promote their survival and
repair (Bringmann et al., 2006; Reichenbach and Bringmann,
2013), and they have been seen to enhance RGC survival (Garcia
et al., 2002; Ruzafa et al., 2018). Therefore, in the CNS, PRGFmay
interact with these glial cells as it contains growth factors known
to accelerate cell proliferation, stimulate differentiation and
promote cell survival (O’kusky et al., 2000; Jin et al., 2002).
Among the growth factors present in PRGF, those implicated
in proliferation include platelet-derived growth factor (PDGF),
transforming growth factor beta (TGF-β), vascular endothelial
growth factor (VEGF), fibroblast growth factor (FGF), epidermal
growth factor (EGF), insulin-like growth factor I (IGF-I) and
nerve growth factor (NGF: (Orive et al., 2009).
In light of the neuroprotective and pro-survival properties of
PRGF, and knowing that PRPs are being used to treat retinal
disorders (Nadal et al., 2012; Arias et al., 2019); we aimed to
determine whether PRGF stimulates Müller cell survival and if it
provides neuroprotection to RGCs. The effect of the PRGF on
these two cell types were studied separately and together in a well-
established adult culture system (Garcia et al., 2002; Garcia and
Vecino, 2003; Ruzafa and Vecino, 2015; Vecino et al., 2015;
Pereiro et al., 2020). In addition, since PRGF contains
molecules with other activities and some that are implicated in
immune responses (Anitua et al., 2015b), we set out to define the
cytokines that could be implicated in the effects in PRGF. Finally,
in order to relate the presence of cytokines in PRGF with its effect
on retinal cells, we set out to suppress the possible pro-
inflammatory response of PRGF through heat inactivation, or
by adding the anti-inflammatory drug dexamethasone or
antibodies against the three major pro-inflammatory cytokines
(IL-1β, IL-6, and TNFα), studying how the inhibition of the
inflammatory response affects RGCs.
MATERIALS AND METHODS
Study Design
On the present study, the effect of the PRGF was analyzed on
different retinal cell cultures and the cytokines in the PRGF were
quantified (Figure 1).
Porcine Samples
Adult porcine eyes (n  20) and blood (n  5) were obtained at a
local slaughterhouse and the eyes were transported to the
laboratory on ice in CO2-independent medium (Life
Technologies, Carlsbad, CA, United States) with 0.1%
gentamicin. The retinas were obtained from the eyes 1–2 h
after enucleation. All animal experimentation adhered to the
ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research.
Human and Pig PRGF
This study was carried out by qualified personnel in strict
accordance with the tenets of the Helsinki Declaration on
Biomedical Research Involving Human Subjects. Before blood
collection, signed informed consent was obtained from all
subjects once the nature of the study and the possible
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consequences of the study had been explained to them. Human
blood samples were obtained through antecubital vein puncture
and PRGF was obtained as described previously (Anitua et al.,
2015a), with some minor modifications. Briefly, human (n  3)
and porcine (n  5) blood was collected in 5 ml tubes containing
3.8% (wt/vol) sodium citrate. Samples were centrifuged at 460 g
for 8 min at room temperature and the plasma fraction
containing platelets was separated, avoiding the buffy coat and
erythrocytes. The plasma fraction (1 ml) was reconstituted for 1 h
at 34°C with 50 µl calcium chloride (Braun Medical, Melsungen,
Germany) in glass tubes, and the supernatant released was
collected after centrifugation at 460 g for 15 min. Finally, part
of the total volume of the PRGF obtained was heat-inactivated at
56°C for 60 min, following a previously published protocol
(Anitua et al., 2014a), and both the samples (PRGF and
inactive PRGF) were filtered through a filter with a 0.2 μm
pore size of (Fisher Scientific, Madrid, Spain), aliquoted and
stored at −80°C.
Cell Culture
Retinal cell cultures were prepared according to the method
reported previously (Garcia et al., 2002; Ruzafa et al., 2018),
with the following minor modifications. Three types of cultures
were used: 1) RGCs cultured in B27-supplemented Neurobasal-A
medium (Life Technologies, Carlsbad, CA, United States); 2) a
co-culture of RGCs and Müller cells in B27-supplemented
Neurobasal-A medium with 10% fetal bovine serum (FBS: Life
Technologies, Carlsbad, CA, United States); and 3) Müller cell
cultures in DMEM (Life Technologies, Carlsbad, CA,
United States) supplemented with 10% FBS. 1% L-glutamine
(2 mM) and 0.1% gentamycin (50 mg/ml) were added to
all media.
The retinas were dissected out and 8 mm diameter pieces were
obtained with a dissecting trephine (Biomedical Research
Instruments, MD, United States), avoiding the most peripheral
retina and visible blood vessels. The tissue was disrupted
enzymatically with papain at 37°C (Worthington Papain
Dissociation kit, Worthington Biochemical Lakewood, NJ,
United States) for 90 min in the presence of 10% DNAse I
(Worthington Papain Dissociation kit, Worthington
Biochemical Lakewood, NJ, United States) to obtain RGCs, or
for 30 min to obtain Müller cells and for co-cultures. Papain
activity was stopped by adding medium and the tissue was
disaggregated by gentle trituration using pipette tips of
decreasing diameter. Dissociated retinal cells were collected by
a 5 min centrifugation at 300 g and resuspended in medium. The
RGC culture was prepared following the protocol of the
Worthington Papain Dissociation kit (Worthington
Biochemical Lakewood, NJ, United States), plating the
resuspended cells in twenty four well plates on 13 mm poly-L-
lysine (100 μg/ml: Sigma, P4832) and laminin (10 μg/ml: Sigma,
L2020) coated glass coverslips. The cells were maintained in a
FIGURE 1 | Scheme of the analysis of the properties of the PRGF and its effects on retinal cell cultures performed in this study. First, human and porcine blood was
extracted and PRGF was obtained by plasma extraction. The effect of the PRGF was analyzed on three different types of cell cultures: pure RGCs or Müller cell cultures,
and co-cultures of both these cell types. In addition, the presence of cytokines in the human and porcine PRGF was quantified through a Q-plex assay. The heat-
inactivated form of PRGFs were also analyzed. After confirming the presence of cytokines in the PRGF, we checked the effect of the presence of pro-inflammatory
cytokines (IL-1β, IL-6, and TNFα) on the RGCs cultures and co-cultures. We heat-inactivated the PRGF, and we added the inflammatory drug dexamethasone (Dex) or
antibodies against cytokines (anti-cyt) to the PRGF in order to analyze its effect on the cell cultures. The survival effect of porcine and human PRGF on pure Müller cells
cultures were also assessed.
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humidified incubator at 37°C in an atmosphere of 5% CO2. For
the Müller cell cultures and the co-cultures, the entire medium
was changed on day 1 and to maintain all the cells, half of the
medium was replaced every 3 days. The cells were fixed for
10 min with methanol at -20°C after 7 days, before the Müller
cells cultures reached confluence. At least three replicates of each
culture were studied and the procedures were carried out in
triplicate.
PRGF (10%) was added at the beginning of the cell culture and
maintained throughout, and for the Müller cell cultures PRGF
was added in the absence of FBS. To analyze the effect of PRGF in
Müller cells, non-autologous porcine and human PRGF were
used. The RGCs and the co-cultures were subjected to different
experimental conditions (Table 1), using only human PRGF due
to the difficulties in obtaining porcine PRGF.
Dexamethasone (Dex, 1 μM: Sigma Aldrich, St. Louis, MO,
United States) was added to the cultures, or a mix of the three
major pro-inflammatory cytokines at a concentration of 10 ng/ml
each (as recommended by (Madeira et al., 2015): IL-1β, IL-6 and
TNFα (Sigma-Aldrich, St. Louis, MO, United States). To
inactivate these pro-inflammatory cytokines, antibodies against
these cytokines were added to the cultures (at 1 μg/ml, the
concentration recommended by (Madeira et al., 2015): goat
anti-IL-1β and mouse anti-IL-6 (R&D System, Minneapolis,
MN, United States), and rabbit anti-TNFα (Peprotech,
London, United Kingdom) antibodies). The cytokines, in the
presence or absence of their antibodies, were also added from the
beginning of the cultures.
Immunochemistry
The cells were fixed in methanol, washed with PBS
(phosphate-buffered saline, pH 7.4) and immunostained as
described previously (Vecino et al., 2002). After blocking non-
specific antigens with blocking buffer (3% BSA and 0.1%
Triton X-100 in PBS) the cultures were exposed to the
following antibodies: a rabbit polyclonal anti-βIII-tubulin
antiserum (diluted 1:2,000: Promega, Madison, WI,
United States), an RGC marker; and mouse monoclonal
anti-vimentin antibody (diluted 1:10,000: Dako, Glostrup,
Denmark) as specific marker for Müller cells. After again
washing in PBS, antibody binding was detected with the
following secondary antibodies (diluted 1:1,000): anti-rabbit
Alexa Fluor 555 and anti-mouse Alexa Fluor 488 (Life
Technologies, Carlsbad, CA, United States). The cells were
also stained with the DAPI nuclear marker at a dilution of 1:
10,000 (Life Technologies, Carlsbad, CA, United States).
Cell Quantification
The surfaces of the whole 13 mm diameter coverslips were
analyzed and at least three replicates of each culture condition
were analyzed, performing these experiments in triplicate. The
images were taken with an epifluorescence microscope (Zeiss,
Jena, Germany) coupled to a digital camera (Zeiss Axiocam
MRM, Zeiss, Jena, Germany) and using the Zeiss Zen software
(Zeiss, Jena, Germany). A mosaic of the entire coverslip was
analyzed using 359, 488, and 555 nm filters with a 10X objective,
and once the mosaic was defined, the coverslip surface area was
calculated (132.73 mm2). The Zeiss Zen software (Zeiss, Jena,
Germany) was used to count the Müller cell nuclei and for the
mosaic definition, and the RGC density was also analysed. The
cell density was calculated as the mean number of cells/mm2, and
the data were normalized to the control to simplify its
representation.
Multiplex Cytokine Assays
To detect and quantify the cytokines present in the different
PRGF samples, a multiplex enzyme-linked immunosorbent assay
(ELISA) was used (Q-Plex™, Human Cytokine Screen,
110996HU, Quansys Bioscience, Logan, UT, United States),
measuring: IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-
12p70, IL-13, IL-15, IL-17, IL-23, TNFα, and TNFβ. The assay
was performed according to the manufacturer´s instruction,
analysing 100 μl of the different human and porcine PRGF
samples (pig, inactive pig, human, inactive human) in each
well of a 98-well plate Q-Plex™. The standards were measured
in duplicate and the cytokine concentrations were calculated
using a standard curve. All samples were assessed in four
replicates and arithmetic averages were calculated.
Statistical Analyses
Statistical analyses were carried out using the SPSS Statistics
software v. 21.0 (IBM) and, the mean and the standard error
for each condition were calculated. The data from the different
experimental conditions were compared using an analysis of
variance (ANOVA), followed by the Games-Howell test as the
variances were not homogeneous according to a Levene test. For
the multiplex cytokine assays, a non-parametric Kruskal-Wallis
H test was used. The minimum value accepted for significant
differences in all the tests was defined as p < 0.05.
RESULTS
The inflammatory cytokines in the pig and human PRGF were
assessed, quantifying the following cytokines in these PRGF
samples: IL-1α, IL-1ß, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12,
IL13, IL-15, IL-17, IL-23, TNFα and TNFß (Table 2).
When the cytokine concentrations in pig and human samples
were compared, only the IL-8 concentration was significantly
higher in the human PRGF than in the pig PRGF (p < 0.001).
Moreover, heat inactivation did not alter the cytokine
concentrations in either the pig or human PRGFs (their
activity was not assessed). As some individual variability was
detected in the quantification of the cytokines, we analysed the
TABLE 1 | Different experimental conditions to which the RGC cultures and the
co-cultures of RGCs and Müller cells were exposed.
Control (0% PRGF)
Cytokines (IL-1β, IL-6 and TNFα)
10% Human PRGF
10% Inactive Human PRGF
10% Human PRGF + Dex
10% Human PRGF + anti-cytokines
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differences in the cytokine concentrations between individuals.
We detected significant differences between individuals for the
IL-8, IL-12, IL-13, IL-15, IL-17, IL-23 and TNFα (p < 0.05) in the
human PRGF, and for the IL-1ß, IL-10, IL-15, IL-17 and IL-23
(p < 0.05) in the pig PRGF. The remaining cytokines were
relatively homogeneous between individuals, with no
significant differences detected.
In light of the cytokines detected in the PRGF, their
neuroprotective effects were analyzed by initially quantifying the
density of RGCs in the presence or absence of 10% human PRGF
(Figure 2). The density of RGCs was 0.55 ± 0.11 cells/mm2 in
control cultures, considered as 100%, yet a significant decrease in
RGC density was evident in the presence of PRGF (29.29 ± 4.31%,
p < 0.05), similar to that detected when the cultures were exposed
to the pro-inflammatory cytokines IL-1β, IL-6 and TNFα (27.80 ±
8.03%, p < 0.05). Heat inactivation of the PRGF did not affect to
RGC survival (140.36 ± 29.29%), favoring the survival of these cells
to a similar extent as that seen in the control cultures. However, the
TABLE 2 | Concentration (pg/ml) of the cytokines in active and inactive porcine and human PRGF
Cytokine Pig PRGF Inactive pig PRGF Human PRGF Inactive human PRGF
IL-1α 8.15 ± 1.67 10.31 ± 0.87 6.34 ± 2.18 6.55 ± 2.39
IL-1ß 14.65 ± 4.93 20.91 ± 7.06 17.03 ± 4.35 17.01 ± 2.54
IL-2 4.58 ± 1.15 6.93 ± 0.13 4.54 ± 0.54 6.17 ± 1.66
IL-4 0.29 ± 0.28 0.87 ± 0.70 0.39 ± 0.32 0.17 ± 0.17
IL-6 3.61 ± 0.49 5.21 ± 0.18 4.24 ± 1.08 3.99 ± 1.14
IL-8 * 1.32 ± 0.42 1.24 ± 0.05 29.59 ± 5.73 29.21 ± 3.38
IL-10 4.65 ± 1.47 6.85 ± 2.65 7.21 ± 1.52 4.73 ± 1.61
IL-12 4.96 ± 1.11 5.86 ± 2.11 5.00 ± 3.87 6.71 ± 3.90
IL-13 0.37 ± 0.21 0.29 ± 0.22 0.75 ± 0.75 0.35 ± 0.20
IL-15 2.29 ± 0.49 4.54 ± 1.23 7.09 ± 2.79 6.77 ± 1.92
IL-17 4.59 ± 0.21 2.93 ± 1.02 1.68 ± 0.99 2.88 ± 0.97
IL-23 185.47 ± 43.63 242.71 ± 86.04 283.14 ± 214.27 222.54 ± 158.70
TNFα 4.65 ± 4.25 3.76 ± 3.76 6.61 ± 2.99 1.84 ± 1.84
TNFß 18.40 ± 4.64 14.07 ± 9.76 18.15 ± 14.21 14.88 ± 13.96
*(significant differences between pig and human PRGF).
FIGURE 2 | The effect of PRGF on RGC cultures. Images of control adult pig RGC cultures (A) or RGCs maintained in the presence of PRGF (B). The RGCs were
labeled with antibodies against βIII-Tubulin (red) staining the nuclei with DAPI (blue). The percentage of RGCs (C) relative to the controls are represented in the
histograms. RGCs were cultured in the presence of cytokines (IL-1β, IL-6, and TNFα), 10% human PRGF (PRGF), PRGF inactivated by heat, PRGF with dexamethasone
(Dex) and PRGF with antibodies against cytokines (anti-cyt). Significant differences relative to the controls are shown:*p < 0.05. Scale bar  100 μm.
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presence of the inflammatory drug dexamethasone (23.76± 3.76%)
or of antibodies against the pro-inflammatory cytokines (15.69 ±
2.35%) did not reverse the deleterious effect of PRGF on RGCs,
provoking similar survival of RGCs to the PRGF alone (p < 0.05,
Figure 2C). Thus, these cytokines could be at least partially
responsible for the detrimental effect on the PRGF as RGC
survival diminished in their presence alone. However, others
factors in the PRGF must also have a deleterious effect on the
RGCs, as in the presence of the antibodies against these cytokines
the survival of RGCs was still compromised.
Since Müller cells possess neuroprotective properties and
given that PRGF enhances their number, we assessed the effect
of PRGF on the RGCs co-cultured in the presence of Müller cells
in co-cultures (Figures 3A,B). Interestingly, PRGF had a similar
effect on RGCs in co-cultures as in the pure RGC cultures. In the
presence of Müller cells, the RGC density still decreased in the
presence of PRGF (22.67 ± 1.91%) or cytokines (30.89 ± 5.49%)
relative to the control conditions (12.97 ± 1.33 RGCs/mm2, 100%:
p < 0.05). The heat inactivation of PRGF abrogated its deleterious
effects on RGCs (92.22 ± 8.11%), the survival of which was no
different to the controls. However, the presence of
dexamethasone (21.54 ± 2.65%) or the presence of antibodies
against the cytokines (24.99 ± 0.28%) did not revert the
deleterious effects of PRGF on RGCs, diminishing their
survival relative to the controls (p < 0.05, Figure 3C).
In terms of Müller cells, the increase in their number in the
presence of 10% human PRGF was dampened when they were co-
cultured with RGCs (36.09 ± 3.31%) and relative to the control
conditions (209.29 ± 28.43 Müller cells/mm2 as 100%, p < 0.05:
Figure 3B). This decrease in the number of Müller cells was
similar to the witnessed in the presence of the cytokines alone
(40.43 ± 1.24%). Moreover, heat inactivation (73.56 ± 4.8%), the
presence of dexamethasone (47.61 ± 3.46%) or of the antibodies
against the cytokines (36.96 ± 1.88%) did not revert the effect of
PRGF and the density of Müller cells remained lower than in the
control cultures (p < 0.05). This difference in the behavior of
Müller cells in the presence of PRGF is probably due to the
inclusion of FBS in the co-culture medium, which in these co-
cultures had to be maintained for the cells to grow correctly.
Finally, to assess the influence of PRGF on the survival of
Müller cells, the density of Müller cells in the pure cultures was
evaluated in the presence or absence of pig and human PRGF.We
compared the density of Müller cell in positive control where 10%
FBS was added to the medium (569.69 ± 59.85 cells/mm2,
considered as 100%), as opposed to those in which the
medium was supplemented with 10% pig or human PRGF.
DMEM medium without either the FBS or PRGF supplement
served as the negative control, was not increase Müller cell
survival. The density of Müller cells maintained in the
presence of PRGF was less than when these cells were
FIGURE 3 | The effect of PRGF on RGCs and Müller cells in co-culture. Control co-cultures of adult pig RGCs and Müller cells (A) and those maintained in the
presence of PRGF (B). The RGCs (arrows) were labeled with antibodies against βIII-Tubulin (red) and Müller cells (arrowheads) with antibodies against vimentin (green)
and the nuclei were labeled with DAPI (blue). The number of RGCs (C) and Müller cells (D) in the co-cultures relative to the total number of cells in the control condition
(100%) are represented in the histograms. RGCs and Müller cells were co-cultured with cytokines (cyt: IL-1β, IL-6 and TNFα), 10% human PRGF (PRGF), heat
inactivated PRGF, PRGF with dexamethasone (Dex) and PRGF with antibodies against the cytokines (anti-cyt). Significant differences relative to the control conditions
are shown: *p < 0.05. Scale bar  100 μm.
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maintained in the presence of FBS, although in both cases the
cultures reached confluence (Figures 4A,B). When the 10% FBS
was replaced by 10% porcine PRGF there was no significant
difference in the density of Müller cells (74.21 ± 12.19%) relative
to the controls, whereas the Müller cell density did decrease
significantly in the presence of 10% human PRGF (39.44 ± 5.34%,
p < 0.01) relative to the control conditions (100%, Figure 4C).
Nevertheless, the substitution of FBS with PRGF induced an
increase of Müller cells, and Müller cells failed to proliferate or
survive in the absence of either PRGF or FBS.
DISCUSSION
PRGF provides tissues with a pool of growth factors, suggesting
that it may stimulate and accelerate tissue regeneration (Anitua
et al., 2015b). For this reason, PRGF is considered a potential
therapeutic agent suitable to treat neurodegenerative diseases
Anitua et al., 2015a). However, in this study on retinal cells,
we found that PRGF reduced the number of retinal neurons, such
as RGCs, while promoting the increase of Müller glial cells.
The proliferative effects of PRGF were first demonstrated in
dentistry and oral implantology, orthopedics, in the treatment of
skin disorders and sports medicine (Sánchez et al., 2003). Indeed,
several studies have described the potential of PRGF eye drops to
produce tissue regeneration in the ophthalmological field, where
it has advantages over other PRPs (Lopez-Plandolit et al., 2010;
Lopez-Plandolit et al., 2011). Our results demonstrate that PRGF
may induce an increase in Müller cells density. Porcine PRGF is
capable of substituting serum when Müller cells are cultured
alone. This is likely to be due to the growth factors present in the
PRGF, such as IGF-1, PDGF or FGF, powerful stimulators of cell
replication and proliferation (Vahabi et al., 2015).
The ability to induce cells division of PRGF is not only evident
in the pig PRGF but also, to a lesser extent in the human PRGF
that partially activated the division of porcine Müller cells,
showing that this effect of PRGF could be interspecific,
although the pig PRGF increased higher the number of Müller
cells than the human PRGF. This behavior is similar in different
types of cells, because different PRPs, including PRGF, induce a
proliferative response (Vahabi et al., 2015), as seen here in the
Müller cells in the absence of serum. Moreover, different platelet
preparations produce similar proliferative effects on
immortalized human Müller cells (MIO-M1) (Burmeister
et al., 2009). In addition, intravitreal injection of PRPs induces
pre-retinal proliferation of fibroblast-like cells (Pinon et al., 1992)
and these fibroblast-like cells could be Müller cells. Currently,
autologous platelet injections are being used in the clinic as a
treatment for recurrent retinal detachment (Nadal et al., 2012),
and pilot studies are being carried out to use PRGF in retinal
surgery to treat persistent macular holes (Arias et al., 2019),
showing benefits in patients but possibly also associated with
some complication including focal macular epithelial pigmentary
hypertrophy, retinal folds emanating from the macula,
development of epiretinal membrane, among others (Minihan
et al., 1997; Cheung et al., 2005; Nugent and Lee, 2015). The
FIGURE 4 | The effect of PRGF on Müller cell density. Images of adult pig Müller cells cultured in the absence (A) or in the presence of PRGF (B). The Müller cells
were labeled with antibodies against vimentin (green) and the nuclei with DAPI (blue). The number of Müller cells represents the percentage (C) relative to the total number
of Müller cells in the control conditions (100%). Müller cells were cultured with 10% fetal bovine serum (FBS) in control, 10% pig PRGF or 10% human PRGF. Significant
differences of control and human PRGF are shown: **p < 0.01. Scale bar  100 μm.
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success in the clinical uses of PRPs, such as PRGF, could be due to
their proliferative effects on cells like Müller glia.
It has also been suggested that PRGF induces neuroprotection
by activating the anti-apoptotic PI3K/Akt signaling pathway,
and/or through reducing caspase-3, promoting proliferation
and survival in primary neuronal cultures. In addition, PRGF
has been proposed to reduce the number of degenerating neurons
in a mouse model of AD, where it dampens astrocyte reactivity,
prevents the loss of synaptic proteins and stimulates global
improvements in anxiety, learning and memory behaviors
(Anitua et al., 2014b). However, our data show PRGF
compromises the survival of RGCs, even when they are co-
cultured with Müller cells. It is important to note that in these
earlier studies, PRGF obtained from human blood was used in
mouse models (Anitua et al., 2015a) and thus, interspecific
interactions did not appear to affect neuroprotection.
However, we have founded that the porcine and human PRGF
did not exert the same effect on the cultures as was mentioned
previously. Moreover, the concentrations of PRGF used here were
10%, the same as those used in these aforementioned studies of
neurodegenerative diseases (Anitua et al., 2014b; Anitua et al.,
2015a), although these were in vivo studies and the behavior of
the retinal cells in cultures may differ in response to the same
concentration of PRGF. Although the plasma concentrate is
distinct, some results are consistent with our findings, where
other PRPs may produce neurotoxic effects, such as thrombin-
activated platelet-rich plasma, possibly due to the release of
glutamate in neuronal cultures (Bell et al., 2014; Zhou et al.,
2017). Moreover, PRGF contains many different factors that are
also present in PRP, including morphogens and growth factors
(Anitua et al., 2015b), and that exert negative effects on axon
growth in rat brain/spinal cord co-cultures, such as TGF-β1
(Takeuchi et al., 2012). These mechanisms could partially
explain the results obtained here on RGCs.
In co-cultures, the negative effect of PRGF on RGCs survival
was observed as well as when they were maintained in pure
cultures. Müller cells provide structural support, maintain retinal
homeostasis, promote the survival of neurons, and secrete
neurotrophins and growth factors that offer protection to
neurons (Garcia et al., 2003; Vecino et al., 2016). Thus, since
PRGF increases Müller cell number, we expected that the survival
of RGCs would be enhanced in co-culture thanks to their possible
neuroprotective action. However, the presence of Müller cells was
not sufficient to rescue RGCs from the detrimental effects of the
PRGF. In addition, the Müller cells density was weaker in the co-
cultures in presence of PRGF, possibly due to the extra effort of
these cells to maintain the RGCs alive or to other mechanisms not
assessed here. In addition, we observed that the morphology of
the cells dramatically change when they are in co-culture in the
presence of PRGF. The decrease in the survival of both Müller
cells and RGCs suggest that both types of cells are stressed or even
dying. In the first steps of the apoptosis, there is a shrinkage of the
cells (Saraste and Pulkki, 2000) that correspond to the rounded
morphology of Müller cells in this condition.
In order to better understand the effect of PRGF on RGCs and
Müller glia, we analyzed the cytokines that it contains. Some
cytokines have already been defined in PRGF, like IL-6 (Masuki
et al., 2016), IL-8, IL-4 and TNFα (Anitua et al., 2015b), yet here
we confirmed the presence of the 16 selected cytokines analyzed
in five porcine and three human samples: IL-1α, IL-1β, IL-2, IL-4,
IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-15, IL-17, IL-23, IFNγ,
TNFα and TNFβ. Moreover, there were no significant differences
in the cytokine concentrations between porcine and human
PRGF, except for the higher abundance of the pro-
inflammatory cytokine IL-8 in human PRGF.
Despite the wide range of cytokines identified in the PRGF, the
presence of the pro-inflammatory cytokines IL-1α, IL-1β and IL-2
is particularly noteworthy due to their possible contribution to
the neurotoxic and proliferative effects of PRGF. The neurotoxic
effect of IL-1 is evident through an increase in neuronal apoptosis
in the hippocampus and dentate gyrus (Rincon-Lopez et al.,
2016), and in the retina (Kido et al., 2001). Moreover, the
neurotoxicity of IL-1β could be specifically mediated by glial
cells (Thornton et al., 2006), and/or to enhanced endoplasmic
reticulum stress as a result of the disturbance of intracellular Ca2+
homeostasis provoked via NMDARs (Dong et al., 2017). In
addition, IL-2 may also be neurotoxic and produce nervous
tissue damage (Hanisch et al., 1997). However, these
interleukins have also been implicated in proliferation and IL-
1 can stimulate diverse cell types (Rangnekar et al., 1991; Jerde
and Bushman, 2009). Indeed, IL-1α can stimulate proliferation of
neural progenitor cells (Mcpherson et al., 2011) and IL-1β
significantly augments smooth muscle cell proliferation (Zhai
et al., 2004). Furthermore, IL-2 can increase the proliferation of T
lymphocytes (Pesoa et al., 2000) or other cell types like
enterocytes (O’loughlin et al., 2001). However, we do not rule
out the possibility that there are other molecules in addition to
these that could be implicated in these effects. Moreover,
microglial cells may also be implicated in the effect of PRGF
in the retina as we have described a migration of these cells as a
sing of inflammation in presence of PRGF. (Ruzafa et al., 2021).
The presence of the three major pro-inflammatory cytokines
(IL-1β, IL-6 and TNFα (Taki et al., 2007; Zhang and An, 2007) in
the cultures could compromise RGC survival due to the
neurotoxic effect that they can exert (Downen et al., 1999; Ye
et al., 2013). However, the suppression of their effects by adding
antibodies against these cytokines to the PRGF previous to be
added to the cultures was insufficient to prevent RGC death.
Thus, the mechanism implicated in neuronal death triggered by
PRGF appears to bemultifactorial. On the other hand, RGC death
can be reversed by the heat-inactivation of PRGF, which
maintains the biological activity of PRGF but completely
reduces the complement activity and significantly deceases the
presence of IgE (Anitua et al., 2014a). Although the inactivated
PRGF apparently contains the same cytokines as the active PRGF,
and in similar amounts, heat-inactivated PRGF is a safer format
to administrate this therapy, especially for subjects affected by
immune disorders, due to the cytokines activity, that was not
assessed here, may have been compromised. This response could
be due to the reduction in neuronal viability by complement
(Peterson et al., 2017), the inhibition of which could be
neuroprotective (Yang et al., 2013) and sufficient to protect
RGCs from death. In addition, it should be noted that
although inflammatory pathways are implicated in neuronal
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death, the presence of the anti-inflammatory drug
dexamethasone does not enhance the RGCs survival.
Although PRGF has been successfully used in different
medical and surgical specialties, and there is extensive data
indicating that PRP induces tissue regeneration, many of these
studies may not have been sufficiently rigorous or well-controlled,
and their data is often limited, whereas other studies have yielded
contrasting results (Kuffler, 2015). The impact exerted by PRGF is
as yet not fully understood, such as its neurotoxic effect, and as
such its application in ophthalmology must be studied in greater
depth. Indeed, the deleterious effect of PRGF on RGCs
demonstrated in our study should be taken into account when
using it to treat retinal disorders like macular holes. Though a
structural recovery might be achieved, for instance macular hole
closure, probably due to the promotion of increases Müller cell
number, the functional recovery might be limited due to its toxic
effects on RGCs. The differences in the concentrations of the
multitude of factors in PRGF and other PRPs may explain the
variability in the results obtained between different studies
(Vahabi et al., 2015). Indeed, we found significant differences
in cytokine concentrations between individuals and thus, further
animal and clinical studies should be performed to clarify the full
range of properties of PRGF.
In conclusion, PRGF does not offer neuroprotection to RGCs
but rather, it markedly compromises the survival of RGCs, even
when these cells are co-cultured with Müller cells. However, this
effect could be reverted by heat-inactivating the PRGF.
Conversely, PRGF increases Müller cell number, and it may be
a good candidate to stimulate and accelerate tissue regeneration
due to these properties. These responses could be produced by the
presence of several cytokines in PRGF, such as the IL-1α, IL-1β
and IL-2 that are present in both human and pig PRGF. Although
the factors responsible for promoting glial survival in the PRGF
could be the neurotrophins identified previously, other molecules
could also participate in this effect. Therefore, further studies will
be necessary to clarify the effect of PRGF in the nervous system, as
well as the other properties of PRGF, including the implication of
the cytokines it contains.
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